Results 91 to 100 of about 112,050 (329)

Recreational use, analysis and toxicity of tryptamines [PDF]

, 2015
The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a "legal" alternative to internationally controlled drugs.
Mannocchi, Giulio, Pantano, Flaminia, Romolo, Francesco Saverio, Tittarelli, Roberta   +3 more
core   +1 more source

Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population‐Based Study with 367 Million Person Years of Observation over 21 Years

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Findings are contradictory regarding changes in the incidence and prevalence of Parkinson's disease (PD) over time; data for other parkinsonian disorders are rare. Objectives To analyze temporal trends in the incidence and prevalence of eight parkinsonisms (PD, MSA, PSP, CBS, DLB, vascular parkinsonism, drug‐induced parkinsonism ...
Sacha E. Gandhi, Katherine A. Grosset, Prasanth A. Iruthayaraj, Romel Gravesande, Lance Lee, Cathal Doyle, Yoav Ben‐Shlomo, Donald G. Grosset   +7 more
wiley   +1 more source

The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis

Annals of Saudi Medicine, 2014
BACKGROUND AND OBJECTIVES: Many studies were conducted to assess the relationship between Monoamine oxidase B (MAOB) A644G polymorphism and susceptibility to Parkinson disease (PD). However, the results were inconsistent and inconclusive.
Ying Liu, Zhiyun Wang, Benshu Zhang
doaj   +1 more source

Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.

The Canadian Journal of Hospital Pharmacy, 2018
Background Monoamine oxidase B (MAO-B) inhibitors are used to treat the motor symptoms of Parkinson disease. Depression is commonly associated with Parkinson disease, and selective serotonin reuptake inhibitors (SSRIs) are often used for its management ...
Abdullah Aboukarr, Mirella Giudice
semanticscholar   +1 more source

Monoaminergic Neuropathology in Alzheimer's disease [PDF]

, 2016
Acknowledgments This work was supported by The Croatian Science Foundation grant. no. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of ...
Bažadona, Danira, Buée, Luc, Delalle, Ivana, Giovanni, Giuseppe Di, Harrington, Charles R., Hof, Patrick R., Jovanov-Milošević, Nataša, Leko, Mirjana Babić, Silva, Rohan de, Wischik, Claude M., Wray, Selina, Šimić, Goran   +11 more
core   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.

Journal of Medicinal Chemistry, 2016
Aiming at modulating two key enzymatic targets for Alzheimer's disease (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget ligands was properly designed by linking the 3,4-dimethylcoumarin scaffold to 1,3- and
L. Pisani, R. Farina, M. Catto, R. Iacobazzi, O. Nicolotti, S. Cellamare, G. Mangiatordi, N. Denora, R. Soto-Otero, Lydia Siragusa, C. Altomare, A. Carotti   +11 more
semanticscholar   +1 more source

Fluoxetine: a case history of its discovery and preclinical development [PDF]

, 2014
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N, Bergstrom RF, Bravo L, Bremner JD, Burrows GD, Chouinard G, Datla KP, Esther Berrocoso, Juan Antonio Mico, Kreiss DS, Laura Perez-Caballero, Lemberger L, Li Q, Lidia Bravo, Maj J, Nibuya M, Owens MJ, Rutter JJ, Sonia Torres-Sanchez, Stevens JC, Wong DT   +20 more
core   +2 more sources

The role of biotransformation processes in mediating interactions between psychotropic drugs and natural products [PDF]

, 2020
Many patients are not aware that natural products such as fruit juices or plant infusions can cause significant interactions with several drugs, some of which can be dangerous, especially when the medical treatment is for neurological or psychiatric ...
Bacinschi, Nicolae, Chianu, Marin, Mihalachi-Anghel, Maria, Podgurschi, Lilia, Pogonea, Ina, Socea, Bogdan, Ștefănescu, Emil   +6 more
core   +2 more sources

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source